OAM
BEAM icon

Oxford Asset Management’s Beam Therapeutics BEAM Stock Holding History

Oxford Asset Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$2.2M Buy
+122,123
New +$2.65M 0.31% 68

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Oxford Asset Management's BEAM Position: Q1 2020 in Review

Oxford Asset Management opened a new position in Beam Therapeutics (BEAM) in Q1 2020: 122,123 shares worth $2.2M. The stake represents 0.31% of the portfolio and ranks #68 among its holdings.

60 funds tracked by Wall St. Rank hold BEAM as of Q1 2020.

  • Oxford Asset Management held 122,123 shares of Beam Therapeutics worth $2.2M as of Q1 2020.
  • Beam Therapeutics was a new Oxford Asset Management position in Q1 2020.
  • Beam Therapeutics made up 0.31% of Oxford Asset Management's portfolio in Q1 2020, its #68 holding.
  • 60 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.